TY - JOUR
T1 - Repetitive Transcranial Magnetic Stimulation With H-Coil in Alzheimer's Disease
T2 - A Double-Blind, Placebo-Controlled Pilot Study
AU - Leocani, Letizia
AU - Dalla Costa, Gloria
AU - Coppi, Elisabetta
AU - Santangelo, Roberto
AU - Pisa, Marco
AU - Ferrari, Laura
AU - Bernasconi, Maria Paola
AU - Falautano, Monica
AU - Zangen, Abraham
AU - Magnani, Giuseppe
AU - Comi, Giancarlo
N1 - Funding Information:
Funding. Study partly supported through the Italian Ministry of Health (Project CC-2353332 2013) and the Italian Ministry of Foreign Affairs (Joint Laboratory Call 2010).
Publisher Copyright:
© Copyright © 2021 Leocani, Dalla Costa, Coppi, Santangelo, Pisa, Ferrari, Bernasconi, Falautano, Zangen, Magnani and Comi.
PY - 2021/2/18
Y1 - 2021/2/18
N2 - Focal repetitive transcranial magnetic stimulation (rTMS) has been applied to improve cognition in Alzheimer's disease (AD) with conflicting results. We applied rTMS in AD in a pilot placebo-controlled study using the H2-coil. H-coils are suitable for targeting wider neuronal structures compared with standard focal coils, in particular the H2-coil stimulates simultaneously the frontal-parietal-temporal lobes bilaterally. Thirty patients (mean age 70.9 year, SD 8.1; mean MMSE score 16.9, SD 5.5) were randomized to sham or real 10 Hz rTMS stimulation with the H2-coil. Each patient underwent 3 sessions/week for 4 weeks, followed by 4 weeks with maintenance treatment (1 session/week). Primary outcome was improvement of ADAS-cog at 4 and 8 weeks compared with baseline. A trend toward an improved ADAS-cog score over time was observed for patients undergoing real rTMS, with actively treated patients experiencing a mean decrease of −1.01 points at the ADAS-Cog scale score per time point (95% CIs −0.02 to −3.13, p < 0.04). This trend was no longer evident 2 months after the end of treatment. Real rTMS showed no significant effect on MMSE and BDI changes over time. These preliminary findings suggest that rTMS with H-coil is feasible and safe in patients with probable AD and might provide beneficial, even though transient, effects on cognition. This study prompts larger studies in the early stages of AD, combining rTMS and cognitive rehabilitation. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT04562506.
AB - Focal repetitive transcranial magnetic stimulation (rTMS) has been applied to improve cognition in Alzheimer's disease (AD) with conflicting results. We applied rTMS in AD in a pilot placebo-controlled study using the H2-coil. H-coils are suitable for targeting wider neuronal structures compared with standard focal coils, in particular the H2-coil stimulates simultaneously the frontal-parietal-temporal lobes bilaterally. Thirty patients (mean age 70.9 year, SD 8.1; mean MMSE score 16.9, SD 5.5) were randomized to sham or real 10 Hz rTMS stimulation with the H2-coil. Each patient underwent 3 sessions/week for 4 weeks, followed by 4 weeks with maintenance treatment (1 session/week). Primary outcome was improvement of ADAS-cog at 4 and 8 weeks compared with baseline. A trend toward an improved ADAS-cog score over time was observed for patients undergoing real rTMS, with actively treated patients experiencing a mean decrease of −1.01 points at the ADAS-Cog scale score per time point (95% CIs −0.02 to −3.13, p < 0.04). This trend was no longer evident 2 months after the end of treatment. Real rTMS showed no significant effect on MMSE and BDI changes over time. These preliminary findings suggest that rTMS with H-coil is feasible and safe in patients with probable AD and might provide beneficial, even though transient, effects on cognition. This study prompts larger studies in the early stages of AD, combining rTMS and cognitive rehabilitation. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT04562506.
KW - ADAS-cog
KW - Alzheimer's disease
KW - H-coil
KW - neuromodualtion
KW - repetitive transcranial magnetic stimulation
UR - http://www.scopus.com/inward/record.url?scp=85102112961&partnerID=8YFLogxK
U2 - 10.3389/fneur.2020.614351
DO - 10.3389/fneur.2020.614351
M3 - Article
C2 - 33679572
SN - 1664-2295
VL - 11
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 614351
ER -